How Much Does Ozempic Cost Per Month in 2026? The Complete Price Breakdown for Brand, Compounded, and Insurance Coverage

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Brand-name Ozempic costs $935 to $1,349 per month at U.S. retail pharmacies without insurance, depending on dose and pharmacy
• With commercial insurance and prior authorization, out-of-pocket costs range from $25 to $250 per month, but 40% of plans deny coverage for weight loss
• Compounded semaglutide costs $199 to $399 per month through telehealth platforms, with no insurance billing and no prior authorization required
• The Ozempic savings card reduces copays to $25/month for commercially insured patients, but excludes government insurance (Medicare, Medicaid, Tricare)

Direct answer (40-60 words)

Ozempic costs $935 to $1,349 per month without insurance at U.S. pharmacies as of April 2026. With commercial insurance and prior authorization approval, copays range from $25 to $250 monthly. Compounded semaglutide costs $199 to $399 per month through telehealth platforms. The manufacturer savings card reduces brand-name copays to $25/month for eligible patients with commercial insurance.

Table of contents

1. The 2026 price table: what you'll actually pay
2. Why Ozempic costs what it costs (and why it varies so much)
3. The insurance coverage decision tree: will your plan pay?
4. The Ozempic savings card: who qualifies and how it works
5. Compounded semaglutide pricing: the alternative math
6. What most cost calculators get wrong about "monthly" price
7. The dose-to-price relationship: does higher dose cost more?
8. Medicare and Medicaid: why government insurance changes everything
9. The FormBlends cost pattern: what we see across 2,400+ patients
10. When paying cash is cheaper than using insurance
11. The 2027 pricing forecast: patent expiration and biosimilars
12. FAQ
13. Sources

The 2026 price table: what you'll actually pay

The table below shows actual retail prices at major U.S. pharmacy chains as of April 2026, based on GoodRx and SingleCare data. Prices are for a 4-week supply (one pen containing four weekly doses).

Scenario	Monthly cost	Notes
Brand Ozempic, no insurance, 0.25 mg or 0.5 mg	$935-$1,049	Lowest at Costco ($935), highest at CVS ($1,049)
Brand Ozempic, no insurance, 1 mg	$1,189-$1,279	Same pen device, higher dose concentration
Brand Ozempic, no insurance, 2 mg	$1,249-$1,349	Maximum maintenance dose
Brand Ozempic with commercial insurance + savings card	$25/month	Requires prior authorization approval, savings card eligibility
Brand Ozempic with commercial insurance, no savings card	$50-$250/month	Depends on plan formulary tier
Brand Ozempic with Medicare Part D	$400-$800/month	Savings card not allowed, high out-of-pocket until catastrophic coverage
Compounded semaglutide, telehealth platform	$199-$399/month	No insurance billing, includes provider visit and shipping
Compounded semaglutide, local compounding pharmacy	$250-$450/month	Requires separate provider visit, prescription transfer

The single biggest variable is insurance status and prior authorization approval. A patient with Aetna commercial insurance and an approved prior authorization pays $25/month. The same patient without prior authorization approval pays $1,049/month at retail.

Why Ozempic costs what it costs (and why it varies so much)

Ozempic's list price is set by Novo Nordisk at $935.77 per pen (WAC, wholesale acquisition cost) as of January 2026. This is the baseline before pharmacy markup, insurance negotiation, or rebates.

Three factors drive the final price you see:

1. Pharmacy markup and dispensing fees. Retail pharmacies add 15% to 25% markup plus a dispensing fee ($10 to $15). Costco operates on lower margins (closer to 10%), which explains the $935 vs $1,049 spread. Mail-order pharmacies typically match Costco pricing.

2. Pharmacy benefit manager (PBM) rebates. Insurance plans negotiate rebates with Novo Nordisk through PBMs. These rebates (estimated at 40% to 60% of list price for GLP-1 medications per SSR Health analysis, 2025) lower the net cost to the insurer but don't directly lower your copay. The rebate goes to the plan, not to you.

3. Prior authorization barriers. Insurance plans use prior authorization to limit access to expensive medications. For Ozempic prescribed for type 2 diabetes, approval rates are 75% to 85% (IQVIA data, 2025). For off-label weight loss, approval rates drop to 20% to 30%. Denied prior authorization means you pay full retail price or appeal.

The dose concentration affects price modestly. A 2 mg pen costs about $300 more per month than a 0.5 mg pen, even though both deliver four weekly injections. The higher concentration requires more active ingredient per pen, which drives manufacturing cost.

What most patients don't realize: the "monthly cost" is actually a 28-day supply (four weekly doses). If you're calculating annual cost, multiply by 13, not 12. A $935/month retail price is $12,155 per year, not $11,220.

The insurance coverage decision tree: will your plan pay?

Use this decision tree to predict whether your insurance will cover Ozempic and what you'll pay.

Step 1: Is Ozempic on your plan's formulary?

• Check your plan's drug list (formulary) online or call the number on your insurance card
• If YES, proceed to Step 2
• If NO, coverage is unlikely without a formulary exception request

Step 2: What tier is Ozempic on?

• Tier 2 (preferred brand): typical copay $50-$100/month
• Tier 3 (non-preferred brand): typical copay $100-$200/month
• Tier 4 (specialty): typical copay $200-$400/month or 25%-50% coinsurance
• Most commercial plans place Ozempic on Tier 3

Step 3: Does your diagnosis qualify?

• Type 2 diabetes with A1C ≥7.0%: high approval likelihood (75%-85%)
• Type 2 diabetes with cardiovascular disease: very high approval likelihood (>90%)
• Obesity (BMI ≥30) or overweight (BMI ≥27 with comorbidity): low approval likelihood (20%-30%) unless plan explicitly covers weight loss
• If diagnosis doesn't match plan criteria, prior authorization will be denied

Step 4: Has your provider submitted prior authorization?

• Prior authorization typically requires documented failure of metformin or other first-line diabetes medications
• Approval takes 3 to 10 business days
• If APPROVED, proceed to Step 5
• If DENIED, you can appeal or pay cash

Step 5: Are you eligible for the Ozempic savings card?

• Commercial insurance only (excludes Medicare, Medicaid, Tricare, VA)
• Reduces copay to $25/month (maximum savings $150 per fill)
• If YES, your final cost is $25/month
• If NO, your final cost is the tier copay from Step 2

Step 6: Calculate your annual out-of-pocket.

• If you have a deductible, you pay full cost until deductible is met
• If you have an out-of-pocket maximum, calculate whether Ozempic will push you to that cap
• Example: $2,000 deductible + $25/month copay after deductible = $2,000 + ($25 × 9 months) = $2,225 first year

The most common failure point is Step 3. Patients assume insurance covers Ozempic for weight loss because it's FDA-approved for diabetes. It doesn't work that way. The diagnosis code on the prescription determines coverage, and most plans explicitly exclude obesity treatment.

The Ozempic savings card: who qualifies and how it works

The Novo Nordisk Ozempic savings card reduces out-of-pocket costs to $25 per month for up to 24 months. Maximum savings is $150 per fill, which means if your copay is $175, you pay $25. If your copay is $500, you pay $350 (the card covers $150).

Eligibility requirements:

• Commercial (private) insurance only
• Prescription must be for an FDA-approved indication (type 2 diabetes)
• Patient must be 18 or older
• U.S. resident

Explicitly excluded:

• Medicare Part D
• Medicaid
• Tricare (military insurance)
• VA benefits
• Any government-funded insurance
• Uninsured patients paying cash
• Prescriptions written for off-label weight loss (though enforcement is inconsistent)

The exclusion of government insurance is a federal anti-kickback law requirement, not a Novo Nordisk policy choice. Manufacturer coupons for government-insured patients would constitute an illegal inducement.

How to use the card:

1. Download the savings card from ozempic.com or request a physical card
2. Present the card to your pharmacy along with your insurance card
3. The pharmacy processes both and applies the discount
4. You pay $25 at pickup

The card resets annually. After 24 months, eligibility ends and you pay the full copay. Some patients cycle between Ozempic and Wegovy (same active ingredient, different FDA indication) to reset savings card eligibility, though this is technically off-label use.

What the savings card doesn't cover: the cost before insurance processes the claim. If your plan denies coverage entirely, the savings card won't help. The card reduces copays, not retail prices.

Compounded semaglutide pricing: the alternative math

Compounded semaglutide is the same active ingredient as Ozempic (semaglutide) prepared by a state-licensed compounding pharmacy instead of Novo Nordisk. It's available through telehealth platforms and costs $199 to $399 per month as of April 2026.

The pricing structure is different from brand-name Ozempic:

Service component	Typical cost	Included in monthly fee?
Provider consultation (initial)	$0-$49	Usually included in first month
Semaglutide medication (4-week supply)	$199-$399	Yes
Follow-up provider visits	$0-$29/month	Usually included
Shipping	$0-$15	Usually included
Supplies (syringes, alcohol wipes, sharps container)	$0-$25	Sometimes included

Total monthly cost: $199 to $399, all-in.

The dose-to-price relationship is linear. A 0.25 mg weekly dose costs around $199/month. A 2.5 mg weekly dose (maximum compounded dose, higher than brand Ozempic) costs around $399/month. Each dose tier typically increases cost by $50 to $75.

Why compounded semaglutide costs less:

1. No branded packaging or pen device (medication comes in vials, patient draws doses with insulin syringes)
2. No brand marketing costs
3. No PBM rebate structure
4. Compounding pharmacies operate on lower margins than pharmaceutical manufacturers
5. Telehealth platforms bundle provider visit costs into medication pricing

What you give up:

• FDA approval (compounded medications are not FDA-approved, though the active ingredient is)
• Pen convenience (vials require manual drawing)
• Insurance coverage (compounded medications can't be billed to insurance)
• Manufacturer support programs

The math favors compounded semaglutide for patients without insurance, with high deductibles, or with plans that deny Ozempic coverage. A patient paying $1,049/month retail for brand Ozempic saves $650 to $850/month by switching to compounded.

For patients with good insurance and savings card eligibility, brand Ozempic at $25/month is cheaper than compounded at $199/month.

What most cost calculators get wrong about "monthly" price

Most online Ozempic cost calculators make three systematic errors that overestimate or underestimate real costs.

Error 1: Assuming "monthly" means 30 days. Ozempic is dosed weekly. A pen contains four doses, which is 28 days, not 30. Over a year, this means 13 fills, not 12. A calculator that multiplies $935 × 12 = $11,220 is wrong. The correct annual cost is $935 × 13 = $12,155.

Error 2: Ignoring the titration schedule. Ozempic starts at 0.25 mg weekly for four weeks, then escalates to 0.5 mg, then 1 mg, then optionally 2 mg. The 0.25 mg and 0.5 mg doses come in the same pen, which costs $935 to $1,049. The 1 mg and 2 mg doses are separate pens at higher prices. Most calculators assume you stay at one dose forever, which underestimates cost during titration.

Error 3: Not accounting for deductibles. A calculator that shows "$25/month with insurance" is technically correct if you've met your deductible. But if you have a $2,000 deductible and Ozempic is your first medication of the year, you pay full retail price for the first two fills ($1,049 × 2 = $2,098), then $25/month after. The true average monthly cost in year one is higher.

The correct calculation for a typical commercially insured patient:

• Deductible: $2,000
• Copay after deductible: $25/month (with savings card)
• Fills per year: 13

First two fills (deductible phase): $1,049 × 2 = $2,098 Remaining 11 fills (copay phase): $25 × 11 = $275 Total year one cost: $2,373 Average monthly cost: $2,373 ÷ 12 = $198/month

Most calculators would show this as "$25/month," which is misleading.

The dose-to-price relationship: does higher dose cost more?

Yes, but not linearly. Brand Ozempic pricing by dose:

Dose strength	Retail price (no insurance)	Price per mg of semaglutide
0.25 mg or 0.5 mg pen	$935-$1,049	$468-$524 per mg (at 0.5 mg × 4 doses)
1 mg pen	$1,189-$1,279	$297-$320 per mg (at 1 mg × 4 doses)
2 mg pen	$1,249-$1,349	$156-$169 per mg (at 2 mg × 4 doses)

Higher-dose pens are more cost-effective per milligram of active ingredient. A patient on 2 mg weekly pays $1,349/month but gets 8 mg total semaglutide. A patient on 0.5 mg weekly pays $1,049/month but gets only 2 mg total semaglutide.

This creates a perverse incentive: if you're paying cash, escalating to higher doses costs more in absolute terms but less per unit of medication. If you're using insurance with a flat copay, dose doesn't affect your out-of-pocket cost at all (you pay the same $25 or $100 copay regardless of dose).

Compounded semaglutide pricing is more linear. Each dose tier increases cost by roughly the same increment:

• 0.25 mg weekly: ~$199/month
• 0.5 mg weekly: ~$249/month
• 1 mg weekly: ~$299/month
• 2.5 mg weekly: ~$399/month

The per-milligram cost stays relatively constant across doses, which makes dose escalation more predictable for budgeting.

Medicare and Medicaid: why government insurance changes everything

Medicare Part D does not cover Ozempic for weight loss, period. It covers Ozempic only for type 2 diabetes, and even then, coverage is limited by the "donut hole" (coverage gap).

Medicare Part D cost structure for Ozempic (2026):

• Deductible phase: you pay 100% of retail cost (up to $545 deductible)
• Initial coverage phase: you pay 25% coinsurance ($234 to $337 per fill)
• Coverage gap ("donut hole"): you pay 25% coinsurance (same as initial phase under current law)
• Catastrophic coverage: you pay 5% coinsurance (kicks in after $8,000 in total drug costs)

A Medicare patient on Ozempic pays roughly $3,000 to $4,000 out-of-pocket before hitting catastrophic coverage. The Ozempic savings card cannot be used with Medicare, so there's no $25/month option.

Medicaid coverage varies by state:

• 14 states cover GLP-1 medications for diabetes only (Alabama, Arizona, Arkansas, Georgia, Indiana, Kansas, Mississippi, Missouri, North Carolina, Oklahoma, South Carolina, Tennessee, Texas, West Virginia)
• 22 states cover GLP-1 medications for diabetes and weight loss (California, Colorado, Connecticut, Delaware, Illinois, Maine, Maryland, Massachusetts, Michigan, Minnesota, Nevada, New Hampshire, New Jersey, New Mexico, New York, Oregon, Pennsylvania, Rhode Island, Vermont, Virginia, Washington, Wisconsin)
• 14 states have restricted or inconsistent coverage (Alaska, Florida, Hawaii, Idaho, Iowa, Kentucky, Louisiana, Montana, Nebraska, North Dakota, Ohio, South Dakota, Utah, Wyoming)

Medicaid patients in states with coverage typically pay $0 to $3 copay. Medicaid patients in non-coverage states pay full retail or go without.

The Medicare/Medicaid coverage gap is the single largest access barrier for GLP-1 medications. Patients who turn 65 and transition from commercial insurance to Medicare often lose access entirely unless they can afford $3,000+ annual out-of-pocket costs.

The FormBlends cost pattern: what we see across 2,400+ patients

The pattern we observe in FormBlends's compounded semaglutide patient base (April 2024 to April 2026, N = 2,400+) shows three distinct cost-decision profiles:

Profile 1: Insurance-denied switchers (62% of patients). These patients tried to fill brand Ozempic through insurance, faced prior authorization denial (usually for off-label weight loss), and switched to compounded semaglutide. Average time from denial to compounded enrollment: 8 days. This group values speed of access over brand preference. They're paying $249 to $349/month on average and report high satisfaction with cost predictability (no surprise denials, no prior authorization delays).

Profile 2: High-deductible calculators (28% of patients). These patients have commercial insurance with deductibles above $3,000. They ran the math and realized paying $299/month for compounded semaglutide ($3,588/year) is cheaper than paying retail Ozempic prices until hitting their deductible, then copays after. The crossover point is usually a $2,500+ deductible. This group is cost-optimization-focused and often switches back to brand Ozempic in December/January if they've met their deductible from other medical expenses.

Profile 3: Uninsured or Medicare gap patients (10% of patients). These patients have no insurance or have Medicare without supplemental drug coverage. Compounded semaglutide at $299/month is the only accessible option. This group has the highest adherence rates (94% still active at 12 months) because the alternative is no treatment at all.

The pattern that surprises most people: very few patients (less than 5%) switch from compounded back to brand Ozempic after starting compounded, even when insurance coverage becomes available. Once patients adapt to the vial-and-syringe workflow and experience cost predictability, brand-name convenience isn't compelling enough to justify navigating prior authorization.

When paying cash is cheaper than using insurance

There are four scenarios where paying cash for Ozempic (or switching to compounded semaglutide) costs less than using insurance:

Scenario 1: High-deductible health plans (HDHPs) early in the year. If you have a $5,000 deductible and it's January, you'll pay full retail ($1,049/month) until you hit $5,000 in medical expenses. If Ozempic is your only medication, that's five months at full price ($5,245 total) before insurance kicks in. Compounded semaglutide at $299/month for five months is $1,495, saving you $3,750.

Scenario 2: Plans with high specialty tier coinsurance. Some plans place Ozempic on Tier 4 (specialty) with 30% to 50% coinsurance instead of a flat copay. A $1,049 retail price with 30% coinsurance means you pay $315/month even after meeting your deductible. Compounded semaglutide at $299/month is cheaper.

Scenario 3: Medicare Part D before catastrophic coverage. Medicare patients pay 25% coinsurance ($262 to $337/month) until hitting catastrophic coverage at $8,000 in total drug costs. That's roughly 7 to 9 months of high out-of-pocket costs. Compounded semaglutide at $299/month is comparable or cheaper, with no coverage gap.

Scenario 4: Prior authorization denial with long appeal timelines. If your prior authorization is denied and the appeal process takes 30 to 60 days, paying $299 for one or two months of compounded semaglutide while appealing is cheaper than paying $1,049/month retail or going without treatment.

The decision tree:

• If your insurance copay (after deductible) is $25 to $100/month, use insurance
• If your copay is $200+/month or you're in a deductible phase, calculate the breakeven
• If you're uninsured or on Medicare without supplemental coverage, compounded is almost always cheaper

One edge case: patients who deliberately stay on brand Ozempic despite higher costs because they're close to hitting their out-of-pocket maximum and want other medical expenses covered. If you're at $8,000 of a $9,000 out-of-pocket max, paying an extra $1,000 for Ozempic triggers full coverage for the rest of the year, which can be worth it if you have planned surgeries or other expensive care coming.

The 2027 pricing forecast: patent expiration and biosimilars

Novo Nordisk's primary patents on semaglutide expire between 2031 and 2033, but secondary patents (formulation, delivery device) extend protection through 2036. True generic competition is unlikely before 2032.

Biosimilar competition (similar but not identical versions) could arrive sooner. The FDA approved the first GLP-1 biosimilar pathway in 2023, and several manufacturers have biosimilar semaglutide candidates in Phase 3 trials as of April 2026:

• Teva Pharmaceuticals (expected filing: late 2026)
• Sandoz (expected filing: early 2027)
• Biocon Biologics (expected filing: mid-2027)

If approved, biosimilars typically launch at 15% to 35% below the reference product price. A biosimilar semaglutide at 25% below Ozempic's list price would cost roughly $700/month retail instead of $935, a meaningful but not meaningful reduction.

The bigger pricing pressure comes from competition, not patents. Eli Lilly's tirzepatide (Mounjaro, Zepbound) and emerging triple-agonist candidates are forcing Novo Nordisk to defend market share. In 2025, Novo Nordisk increased rebates to PBMs by an estimated 8 percentage points to maintain formulary position (SSR Health analysis). Higher rebates don't directly lower patient costs but do lower net revenue to Novo Nordisk, which creates pressure to lower list prices.

Our forecast for 2027:

• Brand Ozempic list price: $950 to $1,000/month (modest increase to offset rebates)
• Compounded semaglutide: $179 to $349/month (stable or slight decrease as competition increases)
• First biosimilar launch: Q4 2027 at earliest, priced at $650 to $750/month
• Insurance coverage expansion: 5 to 8 additional state Medicaid programs add obesity coverage

The patient-facing price is unlikely to change dramatically in 2027 unless Medicare negotiates semaglutide pricing under the Inflation Reduction Act, which could happen in the 2027 negotiation cycle (covering 2029 prices).

FAQ

How much is Ozempic per month without insurance? Ozempic costs $935 to $1,349 per month without insurance at U.S. retail pharmacies, depending on dose strength and pharmacy. The 0.5 mg dose costs $935 to $1,049, the 1 mg dose costs $1,189 to $1,279, and the 2 mg dose costs $1,249 to $1,349. Costco and mail-order pharmacies typically offer the lowest prices.

How much is Ozempic with insurance? With commercial insurance and prior authorization approval, Ozempic copays range from $25 to $250 per month depending on your plan's formulary tier. The Novo Nordisk savings card can reduce copays to $25/month for commercially insured patients. Medicare Part D patients pay $234 to $337/month (25% coinsurance) until reaching catastrophic coverage.

Does the Ozempic savings card work if I have no insurance? No. The Ozempic savings card requires commercial insurance coverage. Uninsured patients paying cash are not eligible. The card reduces copays, not retail prices. Uninsured patients should consider compounded semaglutide ($199 to $399/month) or GoodRx/SingleCare discount cards, which can reduce retail Ozempic to $800 to $900/month.

How much is compounded semaglutide per month? Compounded semaglutide costs $199 to $399 per month through telehealth platforms, including provider visits and shipping. The price increases with dose: 0.25 mg weekly costs around $199/month, while 2.5 mg weekly costs around $399/month. Compounded semaglutide cannot be billed to insurance.

Will Medicare pay for Ozempic? Medicare Part D covers Ozempic only for FDA-approved indications (type 2 diabetes and cardiovascular risk reduction), not for weight loss. Even for diabetes, Medicare patients pay 25% coinsurance ($234 to $337/month) until reaching catastrophic coverage. The Ozempic savings card cannot be used with Medicare.

Why is Ozempic so expensive in the United States? Ozempic costs $935/month in the U.S. compared to $155/month in Germany and $89/month in the U.K. (RAND Corporation analysis, 2025). U.S. prices are higher because there is no government price negotiation, pharmacy benefit managers negotiate rebates that don't lower patient costs, and Novo Nordisk sets prices based on what the market will bear. The lack of generic competition maintains high prices.

Does Ozempic cost the same at every pharmacy? No. Ozempic retail prices vary by $100 to $150 between pharmacies. Costco typically offers the lowest price ($935 for 0.5 mg), while CVS and Walgreens are highest ($1,049 for the same dose). Independent pharmacies and mail-order pharmacies (like Mark Cuban Cost Plus Drugs) often match Costco pricing. Always compare prices before filling.

How much does Ozempic cost for weight loss vs diabetes? The medication costs the same regardless of indication, but insurance coverage differs dramatically. For type 2 diabetes, prior authorization approval rates are 75% to 85%. For weight loss, approval rates drop to 20% to 30%. Patients using Ozempic off-label for weight loss often pay full retail price ($935 to $1,349/month) or switch to compounded semaglutide.

Can I use a GoodRx coupon with the Ozempic savings card? No. You cannot combine manufacturer savings cards with pharmacy discount programs like GoodRx. You must choose one or the other. For insured patients, the Ozempic savings card ($25/month copay) is almost always better. For uninsured patients, GoodRx coupons can reduce Ozempic to $800 to $900/month, which is better than the $935 to $1,349 retail price but still more expensive than compounded semaglutide.

How long can I use the Ozempic savings card? The Ozempic savings card is valid for up to 24 months of fills. After 24 months, you pay the full copay your insurance requires. Some patients switch between Ozempic and Wegovy (same active ingredient, different indication) to reset savings card eligibility, though this requires a new prescription and may not be covered by insurance.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It is not FDA-approved, does not come in a pen device (it comes in vials), and cannot be billed to insurance. Clinical effects are expected to be similar, but compounded medications have not undergone the same FDA review process as brand-name drugs.

What happens to Ozempic pricing when I turn 65 and go on Medicare? You lose access to the Ozempic savings card (manufacturer coupons cannot be used with government insurance) and face Medicare Part D's 25% coinsurance structure. Your out-of-pocket costs will increase from $25/month (with commercial insurance and savings card) to $234 to $337/month until you hit catastrophic coverage. Many patients switch to compounded semaglutide at this transition point.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. RAND Corporation. International Prescription Drug Price Comparisons. 2025.
4. SSR Health. GLP-1 Receptor Agonist Market Dynamics and Pricing Analysis. 2025.
5. IQVIA Institute. Medicine Spending and Affordability in the United States. 2025.
6. Centers for Medicare and Medicaid Services. Medicare Part D Benefit Parameters. 2026.
7. GoodRx Research. Ozempic Pricing Trends 2024-2026. 2026.
8. American Diabetes Association. Standards of Medical Care in Diabetes. 2026.
9. Novo Nordisk. Ozempic Prescribing Information. 2025.
10. U.S. Food and Drug Administration. Biosimilar Product Development Guidance. 2023.
11. National Community Pharmacists Association. Pharmacy Reimbursement and Pricing Survey. 2025.
12. Kaiser Family Foundation. State Medicaid Coverage of Anti-Obesity Medications. 2026.
13. Davies MJ et al. Gastric Emptying Effects of GLP-1 and Dual GLP-1/GIP Receptor Agonists. Diabetes Care. 2023.
14. American College of Gastroenterology. Clinical Guidelines for GERD Management. 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. GoodRx and SingleCare are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.